Common questions about Lercapress (FAQ)
Q: Does Lercapress help with anything besides high blood pressure?
A: Regulatory documents indicate that Lercapress is indicated only for the treatment of essential hypertension (high blood pressure) in adult patients. It is intended for patients whose blood pressure is not adequately controlled by one component alone. It is not approved or studied for other conditions outside of managing essential high blood pressure.
Q: How long does Lercapress typically take to start working?
A: The time it takes to see the full effect is generally related to the lercanidipine component, for which the maximal blood pressure lowering effect may become apparent about two weeks after starting the treatment. The enalapril component does begin to act quickly, often within fifteen minutes, but the full intended effect of the combination requires time.
Q: Can Lercapress cause weight gain?
A: Weight gain is not explicitly listed as a common or uncommon side effect in official product information. However, the medicine can cause peripheral oedema (swollen ankles) in some people, which is a form of fluid retention. This oedema is listed as a common effect.
Q: Why do doctors often prescribe Lercapress alongside other medications?
A: Lercapress is designed as a fixed-dose combination (FDC), meaning it already contains two blood pressure medicines in one tablet: enalapril and lercanidipine. This single-pill product is typically used for adult patients whose high blood pressure was not adequately controlled by taking just one blood pressure medicine alone (monotherapy).
Q: Is Lercapress suitable for people who have diabetes?
A: Lercapress is officially contraindicated (must not be used) in patients with diabetes who are already taking blood pressure medicines that contain Aliskiren. Regulatory documents state that monitoring for low blood glucose levels (hypoglycemia) may be appropriate for patients with diabetes.
Q: Is the low dose of Lercapress as effective as the higher dose?
A: Clinical studies have examined both available strengths of Lercapress. Data from these trials indicates that in patients who were previously not responding to enalapril alone, the higher dose was shown to be significantly more effective in lowering blood pressure than the lower dose.
Q: Can Lercapress affect my sleeping patterns?
A: Official product information notes that somnolence (drowsiness or sleepiness) is listed as a rare undesirable effect of the lercanidipine component of the medicine. Somnolence is noted as a potential factor in the official safety profile.
Q: Does Lercapress have a 'rebound' effect if treatment is stopped suddenly?
A: Studies examining the single components of this fixed-dose combination indicate that the abrupt withdrawal of enalapril (one component of Lercapress) has not been officially associated with a rapid or immediate increase in blood pressure.
Q: What are some common reasons people stop taking Lercapress?
A: Based on regulatory trial data, the most common reasons few patients stopped treatment were related to expected side effects. These reasons include occurrences of coughing, peripheral oedema (swollen ankles), flushing, dizziness, and vertigo.
Q: Do I need to have regular blood tests while on Lercapress?
A: Official guidance indicates that specific monitoring may be required in certain patient groups. For example, patients with mild to moderate kidney impairment should have routine monitoring of serum potassium and creatinine levels. For patients on certain concomitant immunosuppressant therapies, periodic monitoring of white blood cell counts is mentioned as necessary.
Q: Does the body build up a tolerance to Lercapress over time?
A: Information derived from long-term studies using the lercanidipine component (one of the active ingredients) did not show the development of tolerance over the one-year follow-up period examined.
Q: Are there any general expectations for monitoring when starting Lercapress?
A: Regulatory safety information emphasizes the importance of frequent and close monitoring in specific situations. This includes monitoring of blood pressure, kidney function (creatinine), and electrolytes (potassium) for patients with existing mild kidney impairment or for those using certain dual blocking therapies.
Q: Is Lercapress safe for older adults or seniors?
A: Official guidelines state that use in older adults involves caution, particularly regarding the need for assessment of renal function (kidney function). Research on the medicine has included subgroup analysis focused on older adults, but initial use involves the need for appropriate medical assessment and caution.
Q: Does Lercapress affect kidney function over time?
A: The medicine is contraindicated in patients with severe kidney impairment. For patients with existing mild to moderate kidney impairment, regulatory documents require routine monitoring of serum potassium and creatinine levels, indicating that careful observation of kidney function is a necessary part of treatment.
Q: Does Lercapress help protect against stroke or heart attack?
A: Research on Lercapress has primarily focused on its ability to lower blood pressure. Official evidence is currently limited regarding the medicine’s long-term association with rates of major cardiovascular events, such as stroke or heart attack, over the course of decades.
Q: Is Lercapress generally considered safe for long-term use?
A: Lercapress is intended for the long-term management of essential hypertension. However, most of the controlled studies evaluating this fixed-dose combination were short-term, lasting typically 8 to 12 weeks. While its purpose is long-term use, the long-term effects on major cardiovascular events are not fully established in available evidence.
Q: How does Lercapress affect the heart rate?
A: Regulatory documents list tachycardia (an increase in heart rate) as an uncommon undesirable effect. While this effect may occur in some individuals, the general impact on heart rate is a point of mention in the safety profile.
